[Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy].
暂无分享，去创建一个
F. G. García Hernández | M. J. Castillo Palma | J. Sánchez Román | C. Ocaña Medina | Eduardo Chinchilla Palomares | Cristina González Pulido
[1] D. Isenberg,et al. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. , 2008, Clinical and experimental rheumatology.
[2] M. T. Camps,et al. Rituximab en el tratamiento de enfermedades autoinmunitarias: resultados del registro de la Asociación Andaluza de Enfermedades Autoinmunes , 2008 .
[3] E. Pérez,et al. Polimiositis y dermatomiositis: incidencia en España (1997-2004) , 2007 .
[4] M. Cooper,et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. , 2007, Arthritis and rheumatism.
[5] C. Mok,et al. Rituximab for refractory polymyositis: an open-label prospective study. , 2007, The Journal of rheumatology.
[6] M. Genovese,et al. A pilot trial of rituximab in the treatment of patients with dermatomyositis. , 2007, Archives of dermatology.
[7] C. Gabay,et al. Rituximab in the treatment of antisynthetase syndrome , 2005, Annals of the rheumatic diseases.
[8] T. Levine. Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.
[9] A. Bohan,et al. Polymyositis and dermatomyositis (second of two parts). , 1975 .